Combination versus single-agent as palliative chemotherapy for gastric cancer

BMC Cancer

Table 3 Univariate and multivariate analysis of overall survival from the start of first-line chemotherapy

Prognostic Factors	Before propensity score matching					After propensity score matching
	Univariate		Multivariate			Univariate		Multivariate
	MS (months)	P value^a	HR	95% CI	P value^b	MS (months)	P value^a	HR	95% CI	P value^b
Gender		0.728					0.688
Male	10					9
Female	10					8
Age (years)		0.012					0.565
< 70	11		1			9
≥ 70	8		1.01	0.80–1.27	0.941	9
PS (ECOG)		< 0.0001					< 0.0001
0, 1	11		1	1		10		1	1
≥ 2	5		1.47	1.13–1.92	0.004	5		1.59	1.10–2.28	0.013
Disease status		0.315					0.336
Primary metastatic	10					8
Recurrent	10					10
Tumor differentiation		0.022					0.215
Well, moderate	12		1			11
Poor	10		1.32	1.06–1.65	0.015	9
Signet ring cell	8		1.64	1.30–2.07	< 0.0001	7
Combined, others	11		1.21	0.96–1.53	0.102	12
Peritoneal metastasis		0.001					0.037
No	11		1			10		1
Yes	9		1.19	1.01–1.40	0.040	7		1.25	0.96–1.64	0.099
Liver metastasis		0.595					0.613
No	11					9
Yes	9					9
Palliative resection		< 0.0001					< 0.0001
No	9		1			8		1
Yes	19		0.42	0.34–0.52	< 0.0001	15		0.59	0.41–0.85	0.005
1st line CTx		< 0.0001					0.322
Single-agent	8		1			8
Combination	11		0.82	0.66–1.02	0.069	10
CTx lines		< 0.0001					< 0.0001
1st line CTx	6		1			6		1
≥ 2nd line CTx	14		0.69	0.59–0.82	< 0.0001	13		0.59	0.45–0.77	< 0.0001
NLR		< 0.0001					0.013
Low	13		1			10		1
High	8		1.35	1.14–1.61	0.001	7		1.25	0.95–1.65	0.111
PLR		< 0.0001					0.539
Low	12		1			9
High	9		1.21	1.02–1.44	0.033	8

^a Log-rank test, ^bCox proportional-hazards regression model
MS median survival, HR hazard ratio, PS performance status, ECOG Eastern Cooperative Oncology Group, CTx chemotherapy, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407